illustration of interior of cell nucleus

Genomic Control of Metabolism Program

Genetic blueprints teach us how genetic, genomic and epigenetic mechanisms control physiology and metabolism in health and disease.


We use sophisticated technology to evaluate the entire genome, making it more likely to find key changes related to disease, and find biomarkers to monitor diseases associated with adipose tissue, liver, and immune cells. By looking at key transcriptional regulatory proteins that turn metabolism genes “on and off,” we are finding disease-causing mechanisms that are amenable to therapeutic interventions.  

What is the focus of our program?

The focus of our program is to analyze the genomic and epigenetic regulatory mechanisms responsible for proper metabolic control to maintain homeostasis. We primarily study diseases in adipose tissue, liver, muscle and immune cells. Particular emphasis is put on defining the role of key transcriptional regulatory proteins and nuclear hormone receptors in metabolic processes at the cellular level, in animal models and in human disease. Another theme of our research is the systems-level analysis of metabolic processes using integrated experimental and bioinformatics approaches. 

How will our research help patients?

Our research includes studies of fundamental physiological mechanisms and pathophysiological processes in metabolic diseases, such as diabetes, obesity, sarcopenia, chronic inflammation, and others, using genomic, epigenetic and systems-level approaches. The methods we use allow us to see the entire genome, making it more likely that we will find key changes related to a particular disease—and find reliable biomarkers to monitor disease. The biomarkers that we discover may be used to diagnose and/or to monitor disease progression and response to therapy. We anticipate that some of the disease-causing mechanisms and networks identified will be amenable to therapeutic interventions using small molecules or biological modulators. Research carried out in the program will therefore lead to better diagnosis and potentially novel therapies of metabolic diseases. 


Program Director Laszlo Nagy, M.D., Ph.D.


Varga T, Mounier R, Patsalos A, Gogolák P, Peloquin M, Horvath A, Pap A, Daniel B, Nagy G, Pintye E, Póliska S, Cuvellier S, Larbi SB, Sansbury BE, Spite M, Brown CW, Chazaud B, Nagy L
Immunity 2016 Nov 15;45(5):1038-1051
Simandi Z, Horvath A, Wright LC, Cuaranta-Monroy I, De Luca I, Karolyi K, Sauer S, Deleuze JF, Gudas LJ, Cowley SM, Nagy L
Mol Cell 2016 Aug 18;63(4):647-61
Pap A, Cuaranta-Monroy I, Peloquin M, Nagy L
Int J Mol Sci 2016 Jul 30;17(8)